Identifying and testing for hereditary susceptibility to common cancers

Ca-A Cancer Journal for Clinicians

Volumn 54, Issue 6, 2004, Pages 309-326

  Sifri, Randa ^a   Gangadharappa, Sarita ^a   Acheson, Louise S ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; FOLIC ACID; INTERMEDIN DERIVATIVE; MISMATCH REPAIR PROTEIN PMS1; MISMATCH REPAIR PROTEIN PMS2; NUCLEIC ACID BINDING PROTEIN; ORAL CONTRACEPTIVE AGENT; PROTEIN MLH1; RALOXIFENE; SULINDAC; TAMOXIFEN; UNCLASSIFIED DRUG;

ACCURACY; BREAST CANCER; CANCER GENETICS; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; COLORECTAL CANCER; CONSULTATION; FAMILIAL CANCER; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC PROCEDURES; GENETIC SUSCEPTIBILITY; HEALTH PRACTITIONER; HUMAN; INFORMED CONSENT; INSURANCE; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; ONSET AGE; OVARY CANCER; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PEDIGREE; PRIORITY JOURNAL; PROFESSIONAL SECRECY; PROSPECTIVE PAYMENT; PSYCHOLOGICAL ASPECT; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

EID: 4344583875     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.54.6.309     Document Type: Review

References (129)

1. Claus ER, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991; 48:232-242.
2. Kinsler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
3. Burke W. Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997; 277:915-919.
4. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
5. Yu HJ, Lin KM, Ota DM, Lynch HT. Hereditary nonpolyposis colorectal cancer: preventive management. Cancer Treat Rev 2003; 29:461-470.
6. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000; 283:617-624.
7. Hull S, Prasad K. Recording between the lines: direct-to-consumer advertising of genetic testing. Hastings Cent Rep 2001;31:33-35.
8. Myers MF, Jorgensen C, Litch J, et al. Public health response to a direct-to consumer marketing campaign for genetic testing for breast and ovarian cancer susceptibility. Abstract #28 presented at: American College of Medical Genetics Annual Meeting; March 6, 2004; Kissimmee, FL.
9. Sifri R, Myers R, Hyslop T, et al. Use of cancer susceptibility testing among primary care physicians. Clin Genet 2003;64:355-360.
10. Wideroff L, Freedman A, Olson L, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 2003;12:295-303.
11. Gramling R, Nash J, Siren K, et al. Family physician self-efficacy with screening for inherited cancer risk. Ann Fam Med 2004;2:130-132.
12. Freedman AN, Wideroff L, Olson L, et al. US physicians' attitudes toward genetic testing for cancer susceptibility. Am J Med Genet 2003; 120A:63-71.
13. Carroll JC, Brown JB, Blaine S, et al. Genetic susceptibility to cancer. Family physicians' experience. Can Fam Physician 2003;49:45-52.
14. Safer v Pack, 677 A. 2d 1188 (NJ App.), appeal denied, 683 A. 2d 1163 (NJ 1996).
15. Pate v Threlkel, 661 So. 2d 278 (Fla. 1995).
16. Clayton EW. Ethical, Legal, and Social Implications of Genomic Medicine, in Guttmacher AE, Collins FS, Drazen JM (eds). Genomic Medicine: Articles from the New England Journal of Medicine. Baltimore: The Johns Hopkins University Press; 2004:154-155.
17. Sifri R, Wender RC, Paynter NP. Cancer risk assessment from family history: gaps in primary care practice. J Fam Pract 2002;51:856.
18. Acheson LS, Wiesner GL, Zyzanski SJ, et al. Family history-taking in community family practice, implications for genetic screening. Genet Med 2000;2:180-185.
19. Sweet K, Bradley T, Westman J. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol 2002;20:528-537.
20. Church J, McGannon E. Family history of colorectal cancer: how often and how accurately is it recorded? Dis Colon Rectum 2000; 43:1540-1544.
21. Acheson LS, Stange KC, Wiesner GL. Validation of the GREAT system for automated collection of the cancer pedigree. Platform presentation at: American Society of Human Genetics Annual Meeting; October 17, 2002; Baltimore, MD.
22. Emery J, Walton R, Murphy M, et al. Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. BMJ 2000;321:28-32.
23. Euhus, D. CancerGene. Available at: www. swmed.edu/home¶ges/cancergene/. Accessed March 11, 2004.
24. Hampel H, Sweet K, Westman JA, et al. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 2004;41:81-91.
25. Yoon PW, Scheuner MT, Khoury MJ. Research agenda for family history tools: analytic validity, clinical validity, clinical utility, and ethical. Legal and social implications. Abstract #300 presented at: American College of Medical Genetics Annual Meeting; March 7, 2004; Kissimmee, FL.
26. National Society of Genetic Counselors, Inc. home page. Available at: www.nsgc.org/. Accessed March 11, 2004.
27. Bennett RL. The family medical history. Prim Care 2004;31:479-495.
28. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
29. Bennett RL, Allain D, Baker D, et al. Genetic counselor training programs in the United States, capacities and needs: a report of the National Society of Genetic Counselors (NSGC). Abstract #31 presented at: American College of Medical Genetics Annual Meeting; Kissimmee, FL; March 6, 2004.
30. Cancer genetics services directory. Available at: www.nci.nih.gov/search/geneticsservices/.Accessed March 11, 2004.
31. Myriad Genetics, Inc. home page. Available at: www.myriad.com. Accessed March 11, 2001.
32. GeneReviews at GeneTests: medical genetics informatics resource. Familial adenomatous polyposis [database online]. Seattle, WA: University of Washington; 1997-2004. Available at: www. genetests.org. Accessed March 11, 2004.
33. GeneReviews at GeneTests: medical genetics informatics resource. BRCA1 and BRCA2 hereditary breast/ovarian cancer [database online]. Seattle, WA: University of Washington; 1997-2004. Available at: www.genetests.org. Accessed March 11, 2004.
34. Marteau TM, Lerman C. Genetic risk and behavioural change. Br Med J 2001;322:1056-1059.
35. King MC, Marks JH, Mandell JB, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646.
36. Thull D, Vogel V. Recognition and management of hereditary breast cancer syndromes. Oncologist 2004;9:13-24.
37. Croyle R, Lerman C. Risk communication in genetic testing for cancer susceptibility. J Natl Cancer Inst Monogr 1999;25:59-66.
38. Kash KM, Ortega-Verdejo K, Dabney MK, et al. Psychosocial aspects of cancer genetics: women at high risk for breast and ovarian cancer. Semin Surg Oncol 2000;18:333-338.
39. Olopade O. The Emerging Role of Genetics in Clinical Cancer Care, in Perry MC, Whippen D, Harrington R (eds). 1998 ASCO Educational Book: 34th Annual Meeting, Los Angeles, May 16-19, 1998. Alexandria, VA: American Society of Clinical Oncology; 1998: 210-216.
40. Wilkie T. Genetics and insurance in Britain: why more than just the Atlantic divides the English-speaking nations. Nat Genet 1998; 20:119-121.
41. Matloff E, Shappell H, Brierley K, et al. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 2000; 18:2484-2492.
42. Genetics laws and legislative activity. National Conference of State Legislatures Web site. Available at: www.ncsl.org/programs/health/ genetics/charts.htm. Accessed March 11, 2004.
43. American College of Medical Genetics home page. Available at: www.acmg.net. Accessed March 11, 2004.
44. Lehmann LS, Weeks JC, Klar N, et al. Disclosure of familial genetic information: perceptions of the duty to inform. Am J Med 2000;109:738-739.
45. GeneTests home page. Developed by the University of Washington-Seattle. Available at: www.genetests.org/. Accessed March 11, 2004.
46. Genetic Alliance home page. Available at: www.geneticalliance.org/. Accessed March 11, 2004.
47. de Jong MM, Nolte IM, te Meerman GJ, et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 2002;39:225-242.
48. Wooster R, Weber B. Breast and ovarian cancer. N Engl J Med 2003;348:2339-2347.
49. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000;342:564-571.
50. Barnes-Kedar I, Plon S. Counseling the at risk patient in the BRCA1 and BRCA2 era. Obstet Gynecol Clin North Am 2002;29: 341-366.
51. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-128.
52. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-1316.
53. Peto J, Collins N, Barefoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-949.
54. Morrow M. Identification of the woman at risk for breast cancer: problem solved? Recent Results. Cancer Res 1999;151:85-95.
55. Tchou J, Morrow M. Available models for breast cancer risk assessment: how accurate are they? J Am Coll Surg 2003;197:1029-1035.
56. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-1886.
57. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-651.
58. McTiernan A, Kuniyuki A, Yasui Y, et al. Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 2001;10:333-338.
59. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730-1736.
60. Couch F, DeShano M, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-1415.
61. Domchek S, Eisen A, Calzone K, et al. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003; 21:593-601.
62. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations: risk factor analysis and implications for genetic testing. JAMA 1997;278:1242-1250.
63. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16: 2417-2425.
64. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-158.
65. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 1995;273:577-585.
66. Smith R, Saslow D, Sawyer K, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003;53:141-169.
67. Orel SG, Schnall MD, Newman RW, et al. MR unaging-guided localization and biopsy of breast lesions: initial experience. Radiology 1994;193:97-102.
68. Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000;215:267-279.
69. Kriege M, Brekelmans CTM, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. Magnetic Resonance Imaging Screening Study Group. N Engl J Med 2004;351:427-437.
70. Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic pathologic correlation. Radiology 1994;190:485-493.
71. Friedenson, B. Assessing and managing breast cancer risk: clinical tools for advising patients. MedGenMed [serial online] 2004;6.
72. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-1210.
73. Narod S, Dubé M, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-1779.
74. Modan B, Hartge P, Hirsh-Yechezkel M, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235-240.
75. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002;360:187-195.
76. Jernstrom H, Lubinski J, Lynch HT, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2004;96:1094-1098.
77. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
78. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. JAMA 2001;286:2251-2256.
79. Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer 2002;86:218-221.
80. Dickler MN, Norton L. The MORE trial: multiple outcomes for raloxifene evaluation - breast cancer as a secondary end point: implications for prevention. Ann NY Acad Sci 2001;949: 134-142.
81. Hartmann LC, Schaid EJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
82. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-1062.
83. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-1471.
84. Rebbeck T, Lynch H, Neuhausen S, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622.
85. Kauff N, Satagopan J, Robson M, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615.
86. Smith RA, Cokkinides V. Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43.
87. Culler D, Grimes S, Acheson LS, Wiesner GL. Cancer genetics in primary care. Prim Care 2004;31:649-683.
88. HNPCC CME Advisory Committee. Identifying and managing risk for hereditary nonpolyposis colorectal cancer and endometrial cancer (HNPCC) [monograph]. Chicago: American Medical Association, 2001. Available at: www.ama-assn.org/ama/pub/category/ 10183.html.Accessed September 2, 2004.
89. Cao X, Eu KW, Seow-Choen F, et al. APC mutation and phenotypic spectrum of Singapore familial adenomatous polyposis patients. Eur J Hum Genet 2000;8:42-48.
90. Cao Y, Pieretti M, Marshall J, et al. Challenge in the differentiation between attenuated familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer: case report with review of the literature. Am J Gastroenterol 2002;97:1822-1827.
91. Sampson JR, Dolwani S, Jones S, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet 2003;362:39-41.
92. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348:791-799.
93. Enholm S, Hienonen T, Suomalainen A, et al. Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. Am J Pathol 2003;163:827-832.
94. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001;121:198-213.
95. Offit K. Clinical Cancer Genetics: Risk Counseling and Management. New York: Wiley-Liss; 1998.
96. Tiret A, Taiel-Sartral M, Tiret E, Laroche L. Diagnostic value of fundus examination in familial adenomatous polyposis. Br J Ophthalmol 1997;81:755-758.
97. Aretz S, Uhlhaas S, Caspari R, et al. Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 2004;12:52-58.
98. Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 1999;31:412-416.
99. Norton ID, Geller A, Petersen BT, et al. Endoscopic surveillance and ablative therapy for periampullary adenomas. Am J Gastroenterol 2001;96:101-106.
100. Thorson AG, Faria J. Familial adenomatous polyposis, hereditary nonpolyposis colon cancer, and familial risk: what are the implications for the surgeon? Surg Clin N Am 2000;9:683-697; discussion 699-701.
101. King JE, Dozois RR, Lindor NM, Ahlquist DA. Care of patients and their families with familial adenomatous polyposis. Mayo Clin Proc 2000;75:57-67.
102. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-1059.
103. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
104. Higuchi T, Iwama T, Yoshinaga K, et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in Familial Adenomatous Polyposis patients. Clin Cancer Res 2003;9:4756-4760.
105. Phillips RK, Wallace MH, Lynch PM, et al. A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. FAP Study Group. Gut 2002;50:857-860.
106. NCNN practice guidelines in oncology v1 2001. National Comprehensive Cancer Network Web site. Colorectal screening guidelines. Available at: www.nccn.org/physician_gls/PDF/ colorectalℬ reening.pdf. Accessed August 6, 2004.
107. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-107.
108. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colon adenomas. N Engl J Med 2003;348:891-899.
109. Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 1998;129:517-524.
110. Soravia C, Berk T, Madlensky L, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998;62:1290-1301.
111. Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997;336:823-827.
112. Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995;76:2427-2433.
113. Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 2002;45:127-134; discussion 134-126.
114. Drucker L, Shpilberg O, Neumann A, et al. Adenomatous polyposis coli I1307K mutation in Jewish patients with different ethnicity: prevalence and phenotype. Cancer 2000;88:755-760.
115. Woodage T, King SM, Wacholder S, et al. The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet 1998;20:62-65.
116. Figer A, Shtoyerman-Chen R, Tamir A, et al. Phenotypic characteristics of colo-rectal cancer in I1307K APC germline mutation carriers compared with sporadic cases. Br J Cancer 2001; 85:1368-1371.
117. Wagner A, Barrows A, Wijnen JT, et al. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 2003;72:1088-1100.
118. Wijnen JT, Vasen HF, Khan PM, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998;339:511-518.
119. Renkonen E, Zhang Y, Lohi H, et al. Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer. J Clin Oncol 2003;21:3629-3637.
120. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-1456.
121. Vasen HF. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 2000;18:81S-92S.
122. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81:214-218.
123. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-1027.
124. Kolodner RD, Tytell JD, Schmeits JL, et al. Germ-line MSH mutations in colorectal cancer families. Cancer Res 1999;59:5068-5074.
125. Berends MJ, Wu Y, Sijmons RH, et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 2002; 70:26-37.
126. Charames GS, Millar AL, Pal T, et al. Do MSH6 mutations contribute to double primary cancers of the colorectum and endometrium? Hum Genet 2000;107:623-629.
127. Wagner A, Hendriks Y, Meijers-Heijboer EJ, et al. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 2001;38:318-322.
128. Ramsey S, Clarke L, Etzioni R, et al. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001; 135:577-588.
129. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108:1405-1411.